Kornimate/medical-research-clean huggingface dataset:
mindfulness during covid-19

Conditions: Migraine Disorders; Stress; Anxiety

Summary: the objective of this study is to provide remote mindfulness session(s) to help during the covid-19 pandemic.

the objective of this study is to provide remote mindfulness session(s) to help during the covid-19 pandemic.the investigators are interested in targeting patients with migraine, providers, faculty and staff. the investigators are hopeful that this will positively impact overall well-being at this stressful time. the investigators are interested in assessing feasibility, accessibility, and overall interest of an online mindfulness intervention in these populations at this time.

Eligibility criteria:
inclusion criteria: * any person interested in participating in the mindfulness session will be eligible to complete the pre/post surveys and participate in the mindfulness session. exclusion criteria: * none

Keywords: covid-19
hormonal stimulation in iui treatment: is clomifen combined with ethinyl estradiol better, worse or equal to menopur

Conditions: Subfertility

Summary: what is the best medication for hormonal stimulation in cycles with high intra-uterine insemination: tablets of clomifen (5 days) followed by tablets of ethinyl estradiol (5 days) or daily injections with human menopausal gonadotropin (menopur)?


Eligibility criteria:
inclusion criteria: * women younger than 42 years old * infertility of at least one year * normal tubal, pelvic and uterine anatomy * semen with total motility count of at least 5 million (at least one sample) exclusion criteria: * premature ovarian failure * medical history of tubal or ovarian surgery * tubal or pelvic adhesions
plethysmographic waveform for monitoring the quality of cardiopulmonary resuscitation

Conditions: Cardiopulmonary Arrest; Cardiopulmonary Resuscitation; Return of Spontaneous Circulation; Pulse Oximeter Plethysmographic Waveform

Summary: cardiopulmonary resuscitation(cpr) is the key to success for high-quality early cardiopulmonary resuscitation, and its success in the restoration of spontaneous circulation (rosc), therefore, monitoring the quality of cardiopulmonary resuscitation and early identification rosc is very important. now there is no an easy, non-invasive and real-time method to monitor the quality of cpr. in this study the investigators hypothesis the pulse oximeter waveform can real-time monitor the quality of cpr ,and feedback the quality of cpr to the physicians.


Eligibility criteria:
inclusion criteria: * cardiopulmonary arrest, without do-not-resuscitation(dnr) patients * after cardiac arrest, there is no more than 10 minutes until basic life support. * must be carried out advanced life support (tracheal intubation and end-tidal carbon dioxide monitoring) * comply with ethical requirements and signed informed consent exclusion criteria: * dnr patients * rib fractures * hemorrhagic shock caused cardiac arrest * severe anemia, hemoglobin less than 7g/dl * tension pneumothorax without closed drainage * pulmonary embolism or pericardial tamponade caused cardiac arrest * onychomycosis * people who paint fingernails * clearly influential peripheral oximetry underlying diseases (such as raynaud's phenomenon, vasculitis) * the study physicians believe there is any case is not suitable for inclusion.
biocleanse tibialis tendon anterior cruciate ligament (acl) study

Conditions: Anterior Cruciate Ligament Rupture

Summary: to compare the outcome of anterior cruciate ligament (acl) reconstruction performed using the tibialis allograft to historical outcomes of acl reconstruction patients and to establish if any correlation exists between the age of the graft donor and the clinical outcomes.

this is a single-arm, single site, pilot study in patients with a ruptured acl. a total of fifty (50) subjects will be enrolled in this trial. all patients will have been scheduled to undergo acl reconstruction and will receive a biocleanse tibialis allograft as part of the normal standard of care practiced by the treating surgeon. follow up is for 2 years. however, there is no assignment of graft, specific to donor age, to the patients. all treatment will follow standard of care and this study assumes that there will be a normal distribution of graft donor ages, from 18 to 65 years of age. patient outcomes will be compared between the 2 groups of tendon donor ages. neither the surgeon nor the patient will be aware of the age of the graft donor, per typical standard of care.

Eligibility criteria:
inclusion criteria: 1. study subjects will be limited to those subjects undergoing allograft anterior cruciate ligament reconstruction surgery 2. meniscal injuries may be included 3. isolated, unilateral anterior cruciate ligament injury. 4. all subjects will have a minimum age of eighteen (18) years and a maximum of sixty (60) years. 5. both male and non-pregnant female subjects will be included. 6. to facilitate follow-up, study subjects will be limited to the local geographic area of the study site and be willing to use the rehabilitation facility and physical therapy schedule assigned by the surgeon. 7. all subjects must be able to read, write, and comprehend instructions and guidelines in english and understand (and sign as an acknowledgment of their understanding) an informed consent declaration. exclusion criteria: 1. no chondral defects 2. failure to comply with or meet all of the inclusion criteria listed above. 3. autograft anterior cruciate ligament surgery on either knee. 4. anterior cruciate ligament injury on contra-lateral leg at any time 5. multi-ligament reconstruction 6. inability to comply with all requirements of this investigation, as well as follow the instructions of the physician. 7. significant systemic disease or conditions which impact overall health or well being or which necessitate chronic medication use. 8. revision anterior cruciate ligament surgery to either knee at anytime 9. exhibiting signs of moderate to severe degenerative joint disease in addition to requiring anterior cruciate ligament surgery. 10. concomitant injuries to the knee or lower extremities requiring treatment, per surgeon's discretion.

Keywords: acl anterior cruciate ligament torn tendon acl repair acl reconstruction
prediabetes intervention with tea

Conditions: Diabetes Mellitus, Type 2; Pre Diabetes

Summary: the goal of this interventional study is investigating the effect of the daily consumption of olive leaves tea on glycemic control of individuals diagnosed with pre-diabetes. the hypothesis of this study is that the integration of olive leaf tea on daily food consumption will favors glycemic control and ameliorate insulin resistance in individuals with pre-diabetes.

this study is a triple-blinded, randomized, placebo-controlled trial with parallel assignment

Eligibility criteria:
inclusion criteria: at least one of three glycemic criteria for pre diabetes as defined by 2022 american diabetes association (ada) guidelines: * fasting plasma glucose level, 100 to 125 mg per deciliter (5.6 to 6.9 mml per liter); * plasma glucose level 2 hours after a 75-g oral glucose load, 140 to 199 mg per deciliter (7.8 to 11.0 mml per liter); * glycated hemoglobin level, 5.7 to 6.4% (39 to 47 mml per mole). exclusion criteria: * current use of medication for lowering blood cholesterol, glucose or hypertension; * history of chronic or severe diseases that may affect study outcomes or limit study participation; * pregnancy and breastfeeding

Keywords: olive leaves diabetes glycaemic control insulin resistance
observational study of methoxy polyethylene glycol epoetin beta daily use in participants on peritoneal dialysis

Conditions: Renal Impairment; Renal Anemia of Chronic Kidney Disease

Summary: this non-interventional, observational study investigates the efficacy, safety and usability of methoxy polyethylene glycol epoetin beta in participants on peritoneal dialysis. participants who were prescribed methoxy polyethylene glycol epoetin beta by their doctor and who meet the selection criteria were to be enrolled and documented in this study for a period of 9 months of treatment with methoxy polyethylene glycol epoetin beta with respect to efficacy, safety and usability.


Eligibility criteria:
inclusion criteria: * participants on peritoneal dialysis * need for erythropoiesis stimulating agent (esa) therapy * prescription of methoxy polyethylene glycol epoetin beta by the doctor exclusion criteria: n/a
evaluation of the impact of a follow-up phone call nurse device in the care of patients with chemotherapy treatment

Conditions: Solid Tumors

Summary: this study evaluate the impact of a follow-up phone call nurse device in the care of patients with chemotherapy treatment, in their quality of life and medico-economic analysis of this follow-up program device.

this study is a monocentric prospective cohort study designed to monitor the care of patients undergoing an intra venous chemotherapy. patients with a solid tumor (200 patients in total), starting a first cycle of intravenous chemotherapy with 21 days cycle will be included in this study. patients will be followed all over the chemotherapy period through regular and defined telephone appointments carried out by a dedicated nurse. during phone call, a specific questionnaire will be used in order to retrieve data regarding patients toxicities, general care, quality of life, ...actions taken following each phone call will also be documented (consultation, hospitalization, prescription,...). the main objective of this study is to evaluate the impact of this telephone follow-up program on the care of patients under chemotherapy treatment. in addition, a medico-economic analysis of this device compared with historical data from the national database sniiram will be done.

Eligibility criteria:
inclusion criteria: 1. patient with a solid tumor. 2. patient starting a first cycle of chemotherapy (+ - targeted therapy). 3. patient starting intravenous chemotherapy including 21-day cycles. 4. patient ≥18 years old. 5. patient affiliated to a social security system in france. 6. patient who signed the informed consent before study inclusion and before any study specific procedure. exclusion criteria: 1. patient already included in another interventional biomedical research. 2. patient who began intravenous chemotherapy. 3. patient who must receive an oral chemotherapy. 4. patient who must be treated with a weekly chemotherapy or with concomitant radiotherapy. 5. patient unreachable by phone. 6. patient with no caregiver who can answer the phone in his place. 7. pregnant or breastfeeding women. 8. any psychological condition, family, geographic or social not to comply with medical monitoring and / or procedures in the study protocol. 9. patient protected by law.
safety of norepinephrine administered through peripheral venous catheter

Conditions: Hypotension

Summary: norepinephrine is a drug that elevates the blood pressure. it is routinely administered through peripheral catheters during surgery. there is a risk of tissue damage in case of leakage of norepinephrine from the catheter to the surrounding tissue. another risk is irregular administration of norepinephrine due to kinking of the peripheral catheter. this could lead to fluctuations in blood pressure. the primary aim of the study is to investigate complications from norepinephrine administered in peripheral venous catheters. the secondary aim is to investigate if comorbidity, placement of the peripheral catheter or the duration of the infusion are associated with a higher rate of complications. 1000 patients will be included. inclusion criteria: patients who will undergo surgery with need for vasopressor support. exclusion criteria: the patient has a central venous catheter, a peripherally inserted central venous catheter or lack of informed consent.

in many hospitals in sweden, norepinephrine is administered through peripheral venous catheters in the operating room. however there are very few studies to support the safety of peripherally administered norepinephrine. norepinephrine of the concentration 8 respectively 40 microg/ml will be investigated. the primary aim of the study is to investigate complications from norepinephrine administered in peripheral venous catheters. the secondary aim is to investigate if comorbidity, placement of the peripheral catheter or the duration of the infusion are associated with a higher rate of complications. the localisation and size of the peripheral venous catheter will be registered. the blood pressure will me measured every 5 minutes and every minute in case of systolic blood pressure over 220 mm hg. the site of administration will regularly be monitored for complications. if subcutaneous infusion of norepinephrine is suspected, the patient will be followed up for up to 48 hours or until hospital discharge.

Eligibility criteria:
inclusion criteria: * patient who has general anesthesia or central blocks * need for vasopressors in the pre, per or postoperative period to maintain adequate mean arterial blood pressure * age ≥18 years exclusion criteria: * the patient has a central venous line * the patient has a peripherally inserted central line * lack of informed consent
a multicenter breast cancer biospecimen registry

Conditions: Breast Cancer

Summary: this study is being performed to collect blood for the development of noninvasive tests that can screen for or diagnose cancer. blood samples will be collected from women who are scheduled to have breast biopsies.


Eligibility criteria:
inclusion criteria: 1. females of all racial and ethnic groups who are 40 years or older. 2. women must: 1. have suspected neoplasm of the breast (birads 4 or 5) based on the results of any breast screening or diagnostic imaging, such as mammogram, and 2. be selected or scheduled for a breast biopsy which has not yet been conducted at the time of enrollment. exclusion criteria: 1. inability to sign informed consent. 2. more than one radiological finding. 3. any current or prior cancer (with the exception of non-melanoma skin cancer or a suspected breast malignancy targeted for biopsy). 4. any known or suspected acute illness or condition - including acute infections - at the time of enrollment or within the previous 30 days. 5. any surgery, hospitalization, or institutionalization (such as in a nursing home) during the previous 3 months. 6. received any experimental therapeutic treatment during the previous 3 months. 7. received any blood product transfusion within the previous 3 months. 8. use of illegal drugs during the previous 3 months. 9. pregnant or nursing at the time of enrollment or in the preceding 12 months.
mesenchymal stem cell transplantation for refractory primary biliary cholangitis

Conditions: Primary Biliary Cirrhosis

Summary: ursodeoxycholic acid is the mainstay treatment medicine for primary biliary cholangitis(pbc). about 1/3 of the patients do not respond to udca, which is defined as refractory pbc. mesenchymal stem cells (msc) has been reported to improve the outcomes of pbc patients. randomization controlled studies are needed to confirm the long term effect of msc treatment for refractory pbc. this study aimed to investigate the safety and efficacy of mesenchymal stem cells in pbc patients that do not respond to udca treatment. this study is an double-blind multicenter randomized and placebo-controlled study. patients with with refractory pbc will be randomly assigned to receive msc treatment plus udca or udca alone (control). three times of msc infusion (0.1-1x10e6 cells/kg body weight) via peripheral vein will be given to the experimental group (once in 4 weeks). the primary outcome is absolute change in alkaline phosphatase. secondary outcomes are changes of other liver function indices such as alt tbil ast ggt, improve of symptoms and liver histology.


Eligibility criteria:
inclusion criteria: 1. informed consent 2. age between 18-70 years old 3. bmi between 17-28 4. meeting at least 2 of the 3 criteria: (1) positive for anti-mitochondial antibody (ama)；(2) elevated alp or ggt；(3) pbc diagnosis confirmed by liver biopsy 5. serum alp \>/=1.67 uln after at leat 6 months treatment with udca 1(3-17mg/kg/day) - exclusion criteria: 1. pregnancy, breast-feeding females 2. use of liver-toxic drugs over 2 week within 6 months prior to recruitment； 3. refractory variceal bleeding, uncontrolled hepatoencephalopathy or uncontrolled ascites. 4. acute of chronic kidney failure. 5. commodities with other liver diseases such as viral hepatitis, alcoholic liver disease, auto-immune hepatitis or liver cancer 6. severe cardiovascular disease； 7. liver transplantation listed patients； 8. alt/ast over 5xuln，or total bilirubin \>85umol/l 9. anticipated need for liver transplantation within 1 year according to mayo risk score 10. other candidates who are judged to be not applicable to this study by doctors

Keywords: primary biliary cirrhosis (now termed as primary biliary cholangitis), mesenchymal stem cell,
online platform for healthy weight loss (poemas)

Conditions: Obesity; Overweight

Summary: clinical trial to test the efficacy of an online platform based on behavior change principles in promoting weight loss among overweight and obese students and employees of the federal university of minas gerais. the hypothesis is that participants of the group which use the platform with or without a dietitian coaching will lose more weight than those allocated to the group who receives dietary and physical activity orientations by educational videos only.


Eligibility criteria:
inclusion criteria: * body mass index \>=25 kg/m2 * intention to lose weight by healthy lifestyle habits * internet access exclusion criteria: * pregnancy * diabetes * heart failure * coronary artery disease * kidney disease * hepatic disease * cancer * phenylketonuria * celiac disease * food allergies * bariatric surgery history * participation in any other weight loss program

Keywords: obesity overweight telemedicine ehealth
efficacy study of agspt201 tablet to treat gastroesophageal reflux disease

Conditions: Gastroesophageal Reflux Disease

Summary: the purpose of this study is to evaluate treatment in gastroesophageal reflux disease (gerd) patients (aged 18\~75) with endoscopically proven gerd treated with agspt201 tablet.

this study is 4,8 weeks, outpatient, multicenter, randomized, double-blinded, active drug comparative, therapeutic confirmatory clinical study to evaluate the efficacy and safety of agspt201 in erosive esophagitis patients.

Eligibility criteria:
inclusion criteria: * aged 18\~75 years * patients whose esophageal lesions graded over la a grade (the severity of lesions is classified by la classification) * patients whose typical reflux symptoms such as heartburn, acid regurgitation, acid reflux and esophagus irritation during the past 3 month * symptoms on at least 2 days of the past 7 days exclusion criteria: * ppi treatment within 4 weeks before dosing or treatment of h2 blocker, sucralfate, prokinase nsaid (except low dose aspirin) within 2 weeks before dosing. * patients whose history of gi tract resection or vagotomy. * barrett's oesophagus greater than 3cm in length and high-grade dysplasia. * acid irrelevant heartburn and regurgitation. * zollinger ellison syndrome * hypersensitive and/or allergy to pantoprazole and/or other ppi * pregnancy and lactation * peptic ulcer * serious hepatic * any other renal, cardiac or haematological disease. * patients participated any other clinical studies during the past 3 months.

Keywords: gerd endoscopy la grade heartburn
intravascular lithotripsy with or without rotational atherectomy for coronary calcified nodule treatment

Conditions: Coronary Artery Disease; Coronary Calcification

Summary: the nodule-shock trial is a prospective, investigator-initiated, single-center, randomized controlled trial designed to compare the efficacy of intravascular lithotripsy (ivl) with or without rotational atherectomy (ra) in patients with coronary calcified nodules (cohort a), and operator-determined vs maximum ivl pulses in patients with non-nodular severe coronary calcium (cohort b).

the trial consists of two cohorts: * patients with calcified nodules (cn) (cohort a) * patients with non-nodular severe coronary calcium (cohort b) randomization will occur as follows: * rotational atherectomy followed by intravascular lithotripsy (ivl) or ivl alone for lesion preparation prior to stenting (cohort a). * operator-determined or maximum ivl pulses prior to stenting. (cohort b) the trial is designed to compare two calcium modification strategies in each cohort with regard to the primary endpoints of post-procedural minimum stent area assessed by optical coherence tomography at the cn site (cohort a) and at the site of maximum calcification (cohort b).

Eligibility criteria:
inclusion criteria * age ≥18 years who signed written informed consent * presence of a clinical indication for coronary intervention * patients undergoing pci for a de novo calcified lesion with planned drug-eluting stent (des) implantation * native coronary artery with significant stenosis defined as: * ≥70% and \<100% stenosis on angiography, or * 50-70% stenosis with evidence of ischemia (positive stress test, ffr ≤ 0.8, or oct minimal lumen area (mla) ≤ 4.0 mm2) * reference vessel diameter: ≥2.5 mm to ≤ 4.0 mm * lesion length: ≥5mm * moderate to severe calcification of the target lesion confirmed by angiography * thrombolysis in myocardial infarction (timi) flow grade 3 at baseline exclusion criteria * cardiogenic shock at the time of procedure * primary pci for st-segment elevation myocardial infarction (stemi) * pregnant, nursing, or childbearing potential without adequate contraception * known allergy or contraindication to dapt (aspirin, clopidogrel, prasugrel, ticagrelor) * planned surgery within 6 months unless dapt can be maintained * life expectancy \<12 months due to a serious medical illness (e.g., advanced cancer, end-stage heart failure) * severe kidney dysfunction (crcl \<30 ml/min) without dialysis * concurrent participation in another investigational study * referral for coronary artery bypass grafting (cabg) after a heart team discussion * angiographic evidence of thrombus at the target lesion * angiographic evidence of significant dissection at the treatment site prior to intervention * lesion with a previously placed stent within 10mm (visual estimate) * last remaining vessel with severely compromised left ventricular function (lvef \<30%) * target lesion within a saphenous vein graft (svg)

Keywords: coronary calcification calcified nodule intravascular lithotripsy rotational atherectomy optical coherence tomography percutaneous coronary intervention
safety and efficacy study in subjects with chronic hcv and underlying hemophilia

Conditions: Hepatitis C Virus

Summary: the primary objective for this study is to evaluate the proportion of subjects who achieve svr12 (hcv rna \< lloq (target not detected) at post-treatment follow-up week 12 in subjects with genotype(gt)-1b, -4 and gt-2, -3


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com. inclusion criteria: * severe hemophilia (defined as \< 1% factor activity level) * infection with the hepatitis c virus (hcv) with underlying hemophilia * males 18 years of age and above * have not been previously treated with an interferon exclusion criteria: * not infected with the hepatitis b virus (hbv) or human immunodeficiency virus (hiv) * chronic liver disease caused by any disease other than chronic hcv infection * presence of bethesda inhibitor * current evidence of or history of portal hypertension